Letermovir for Prophylaxis and Pre-emptive Therapy of Cytomegalovirus Infection in Paediatric Allogeneic Haematopoietic Cell Transplant Patients.

Katharina F KörholzMiriam A FüllerMarc HenniesMalcolm HolterhusSusanne HagedornMartina AhlmannHeike ThorerBirgit BurkhardtAndreas H Groll

Published in: Paediatric drugs (2022)

Letermovir was effective in controlling CMV infection in seropositive paediatric allogeneic HCT recipients and was overall well tolerated. Pending completion of the still ongoing paediatric investigation plans, letermovir will be an important adjunct to our options for control of infectious complications in this special population.

Keyphrases

stem cell transplantation
intensive care unit
emergency department
bone marrow
end stage renal disease
newly diagnosed
cell therapy
prognostic factors
single cell
hematopoietic stem cell
risk factors
low dose
mesenchymal stem cells
cell proliferation
signaling pathway
kidney transplantation
cell cycle arrest